- Rapid Diagnostic Tests (RDTs), offering quick, point-of-care results without the need for complex laboratory infrastructure, are becoming essential tools in disease surveillance, outbreak response, and routine diagnostics across both hospital and homecare settings due to their speed, affordability, and ease of use
- The increasing demand for RDTs is primarily driven by the growing prevalence of infectious diseases, rising need for decentralized healthcare, and advancements in lateral flow and immunoassay technologies that have improved test accuracy and shelf life
- The U.K. dominated the Europe rapid diagnostic tests (RDT) market with the largest revenue share of 29.7% in 2024, supported by government initiatives promoting self-testing, a strong retail pharmacy network, and widespread use of RDTs in COVID-19, influenza, and STI testing. The expansion of e-commerce healthcare services further boosts home-based diagnostics in the country
- Germany is expected to be the fastest growing country in the Europe rapid diagnostic tests (RDT) market during the forecast period, driven by the rising incidence of chronic and infectious diseases, increasing healthcare expenditure, and strong uptake of innovative diagnostic technologies across hospital and ambulatory care settings
- The consumables and kits segment dominated the Europe rapid diagnostic tests (RDT) market with the largest revenue share of 64.3% in 2024, attributed to the high frequency of testing across healthcare settings and ease of availability
